Skip to main content

Zovighian Bernard J's Form 4 filing

Edwards Lifesciences Corp (EW) · filed Feb 13, 2026

Accession no.
0001225208-26-001893
Filed
Feb 13, 2026
Trade date
Feb 12-13, 2026
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.72M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Zovighian Bernard JCIK 0001665141Director, Officer (CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 12, 2026Common StockMOption exerciseAcquired+25,350$59.26+$1,502,241106,326Direct
Feb 12, 2026Common StockSSaleDisposed−2,532$77.13F1−$195,293.16103,794Direct
Feb 12, 2026Common StockSSaleDisposed−19,898$76.61F2−$1,524,385.7883,896Direct
Feb 13, 2026Common StockGGiftDisposed−2,920$0.00$080,976Direct
Feb 13, 2026Common StockGGiftAcquired+2,920$0.00$011,516.55Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 12, 2026Common StockMOption exerciseDisposed−25,350$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F2

This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)